BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Pa
ABT
ABT, ERIC, IVZ
AMAT, GOOGL, ANET, AAPL, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, NVDA, META, SYK, BSX, ORCL, CBOE, PWR, MCK, NOW, ADBE, LYFT, SCHW, MCHP, ISRG, AMZN, ODFL, CRM
CVX, PFE
BIIB
Karen Andersen
Sector Strategist